The following is a summary of the Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript:
Financial Performance:
Apollomics ended 2023 with cash and equivalents of $37.8 million.
The company managed to raise $23.7 million in a financing round associated with its NASDAQ listing in March 2023.
The cash position is projected to support operations into Q1 2025.
The annual spend in research and development was $34.2 million and for general and administrative costs, it was $20.6 million.
There's a marked reduction in the net loss at $172.6 million compared to the previous year's net loss of $240.8 million.
Business Progress:
Apollomics has been making significant headway in the development of its two lead drug candidates, Vebreltinib and Ophthalescelen.
Clinical results are positive with over 500 patients treated with Vebreltinib.
In early 2024, the company received encouraging feedback from FDA on Vebreltinib.
Evanstone received conditional approval in China for commercializing Vebreltinib for lung cancer treatment.
Enrollment is complete for Phase 3 bridging study in China for potential AML treatment, APL 106.
Apollomics successfully listed on NASDAQ in March 2023.
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.